A new study brings researchers closer to better understanding the pathology of the fatty liver disease MASH, which stands for metabolic dysfunction-associated steatohepatitis.

Liver histology plays a much more important role in making decisions about treatment of HCV. Adrian M. Di Bisceglie, MD, FACP, explores the issues.